NAMS vs. SNDX, EWTX, GLPG, AMRX, AGIO, GPCR, AMPH, EVO, DCPH, and CPRX
Should you be buying NewAmsterdam Pharma stock or one of its competitors? The main competitors of NewAmsterdam Pharma include Syndax Pharmaceuticals (SNDX), Edgewise Therapeutics (EWTX), Galapagos (GLPG), Amneal Pharmaceuticals (AMRX), Agios Pharmaceuticals (AGIO), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Evotec (EVO), Deciphera Pharmaceuticals (DCPH), and Catalyst Pharmaceuticals (CPRX). These companies are all part of the "pharmaceutical preparations" industry.
Syndax Pharmaceuticals (NASDAQ:SNDX) and NewAmsterdam Pharma (NASDAQ:NAMS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.
Syndax Pharmaceuticals' return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.
Syndax Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500.
89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by company insiders. Comparatively, 19.5% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Syndax Pharmaceuticals received 356 more outperform votes than NewAmsterdam Pharma when rated by MarketBeat users. However, 100.00% of users gave NewAmsterdam Pharma an outperform vote while only 64.73% of users gave Syndax Pharmaceuticals an outperform vote.
Syndax Pharmaceuticals currently has a consensus price target of $34.42, suggesting a potential upside of 64.12%. NewAmsterdam Pharma has a consensus price target of $33.25, suggesting a potential upside of 64.52%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Syndax Pharmaceuticals.
NewAmsterdam Pharma has lower revenue, but higher earnings than Syndax Pharmaceuticals.
In the previous week, Syndax Pharmaceuticals had 18 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 22 mentions for Syndax Pharmaceuticals and 4 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 0.67 beat Syndax Pharmaceuticals' score of -0.58 indicating that Syndax Pharmaceuticals is being referred to more favorably in the media.
Summary
NewAmsterdam Pharma beats Syndax Pharmaceuticals on 9 of the 15 factors compared between the two stocks.
Get NewAmsterdam Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NewAmsterdam Pharma Competitors List
Related Companies and Tools
